Walter H. Gotlieb
Professor of Ob-Gyn & Oncology
MD, PhD
In addition to his clinical responsibilities, he is involved in scientific research in ovarian cancer as a Project Director at the Lady Davis Research Institute. Together with his team, and particularly Dr. Lau, they have pioneered the use of robotic surgery in gynecologic cancer in Canada. He has lectured around the world, and has proctored robotic surgery multiple times in Canada, China, India and Israel. A recipient of thirteen national and international awards in the area of cancer research, Dr. Gotlieb is widely published, with over 200 peer-reviewed manuscripts in international journals and book chapters.聽
Walter H. Gotlieb completed his medical degree summa cum laude at the Universit茅 Libre de Bruxelles, in his native Belgium, where he went on to obtain board certification in Ob-Gyn and obtained his PhD following an additional two years at the NIH in cancer immunology with an Award of Outstanding Performance. He then obtained a three year fellowship in Gyn-onc at UCLA. Afterwards he was recruited by the by Tel Aviv University, Tel Hashomer Hospital, where he co-founded and built up the Department of Gynecologic-Oncology from 1994 to 2003.
In 2003, he was recruited by 不良研究所. He obtained licenses to practice in Europe, Israel, California, and Canada.
Dr. Gotlieb sits on the Executive Committee of the Society of Gynecologic Oncology of Canada (GOC), he chairs the scientific advisory board of the ICRF Montreal, and sits on the board of Ovarian Cancer Canada (OCC). He is past-president of GOC and served as secretary treasurer of GOC and of the International Gynecologic Cancer Society (IGCS). He was senior editor of the International Journal of Gynecologic Cancer for 10 years.
Dr. Gotlieb's affiliation with the 不良研究所 includes: Professor in the department of Ob-Gyn and the department of Oncology, Director of Surgical Oncology at 不良研究所. He is the Chief of the Department of Obstetrics, Gynecology, & Gynecologic Oncology at the Jewish General Hospital, and Full Member at the Centre for Translational Research in Cancer, and Associate Member at the Division of Experimental Medicine of the Department of Medicine.
In 2012 he completed an executive course in health care management and delivery at the Harvard Business School.
Jeremie Abitbol, Aqsa Munir, Jeffrey How , Susie Lau , Shannon Salvador , Liron Kogan, Roy Kessous , Leslie Breitner , Russell Frank, Beste Kucukyazici,聽Walter H. Gotlieb. The shifting trends towards a robotically-assisted surgical interface: Clinical and financial implications. Health Policy and Technology 9 (2020) 157鈥�165
Kogan L, Matanes E, Wissing M, Mitric C, How J, Amajoud Z, Abitbol J, Yasmeen A, L贸pez-Ozuna V, Eisenberg N, Lau S, Salvador S,聽Gotlieb WH.聽The added value of sentinel node mapping in endometrial cancer. Gynecol Oncol. 2020 Jul;158(1):84-91. doi: 10.1016/j.ygyno.2020.04.687. Epub 2020 Apr 27.PMID: 3234987
Piedimonte S, Frank C, Laprise C, Quaiattini A,聽Gotlieb WH.聽Occult Tubal Carcinoma After Risk-Reducing Salpingo-oophorectomy: A Systematic Review. Obstet Gynecol. 2020 Mar;135(3):498-508. doi: 10.1097/AOG.0000000000003702.PMID: 32028491
Kessous R, Wissing MD, Piedimonte S, Abitbol J, Kogan L, Laskov I, Yasmeen A, Salvador S, Lau S,聽Gotlieb WH. CA-125 reduction during neoadjuvant chemotherapy is associated with success of cytoreductive surgery and outcome of patients with advanced high-grade ovarian cancer. Acta Obstet Gynecol Scand. 2020 Jul;99(7):933-940. doi: 10.1111/aogs.13814. Epub 2020 Feb 5.PMID: 31954071
Abitbol J,聽Gotlieb W, Zeng Z, Ramanakumar A, Kessous R, Kogan L, Pare-Miron V, Rombaldi M, Salvador S, Kucukyazici B, Brin S, How J, Lau S. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
Int J Gynecol Cancer. 2019 Nov;29(9):1341-1347. doi: 10.1136/ijgc-2019-000413. Epub 2019 Oct 9.PMID: 31601648
Octeau D, Kessous R, Klein K, Kogan L, Pelmus M, Ferenczy A, Greenwood CMT, Van Kempen LC, Salvador S, Lau S, Tonin PN, Yasmeen A,聽Gotlieb WH. Outcome-Related Differences in Gene Expression Profiles of High-Grade Serous Ovarian Cancers Following Neoadjuvant Chemotherapy. .Mol Cancer Res. 2019 Dec;17(12):2422-2431. doi: 10.1158/1541-7786.MCR-19-0398. Epub 2019 Sep 17.PMID: 31530633
Kessous R, How J, Abitbol J, Puzhakkal S, Kogan L, Yasmeen A, Salvador S,聽Gotlieb WH, Lau S. Triple tracer (blue dye, indocyanine green, and Tc99) compared to double tracer (indocyanine green and Tc99) for sentinel lymph node detection in endometrial cancer: a prospective study with random assignment.聽Int J Gynecol Cancer. 2019 Sep;29(7):1121-1125. doi: 10.1136/ijgc-2019-000387. Epub 2019 Jul 17.PMID: 31320490
Baloch T, L贸pez-Ozuna VM, Wang Q, Matanis E, Kessous R, Kogan L, Yasmeen A,聽Gotlieb WH. Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1. BMC Cancer. 2019 Jan 10;19(1):44. doi: 10.1186/s12885-018-5250-4.PMID: 30630446
Gotlieb R, Abitbol J, How JA, Ben-Brith I, Abenhaim HA, Lau SK, Basik M, Rosberger Z, Geva N,聽Gotlieb WH, Mintz A. Gender differences in how physicians access and process information. Gynecol Oncol Rep. 2019 Jan 2;27:50-53. doi: 10.1016/j.gore.2018.12.008. eCollection 2019 Feb.PMID: 30662932
